Pharma stock hits upper circuit after securing order from Govt. of India to supply medical kits to Afghanistan

Synopsis:
Shukra Pharmaceuticals secures Rs. 24.06 crore contract from HSCC (India) Limited to supply essential medicines and diagnostic kits to the Technical Mission of India in Kabul, Afghanistan.

Shares of a company involved in the manufacturing and marketing of pharmaceutical products hit a 2 percent upper circuit on Friday, after securing an order worth around Rs. 24 crores from HSCC (India) Limited (a Government of India Enterprise under the Ministry of Housing & Urban Affairs).

With a market cap of Rs. 1,148 crores, the shares of Shukra Pharmaceuticals Limited hit a 2 percent upper circuit at Rs. 26.22 on BSE, as against its previous closing price of Rs. 25.71. The stock has delivered multibagger returns of over 305 percent in the last one year, and has gained by about 29 percent in the last one month.

What’s the News

According to its latest regulatory filings with the BSE, Shukra Pharmaceuticals Limited secured a significant contract by HSCC (India) Limited, a Government of India Enterprise under the Ministry of Housing & Urban Affairs, acting on behalf of the Ministry of External Affairs.

The company has received a Letter of Award (LoA) for the supply of medicines and diagnostic kits to the Technical Mission of India in Kabul, Afghanistan. Valued at Rs. 24.06 crores, the contract covers the supply of essential medicines and diagnostic kits, including packing, forwarding, insurance, and delivery to the designated site in Afghanistan.

Financials & more

Shukra Pharma reported a significant growth in its revenue from operations, showing a year-on-year increase of around 69 percent from Rs. 3.2 crores in Q1 FY25 to Rs. 5.4 crores in Q1 FY26. Similarly, its net profit increased during the same period from Rs. 0.5 crores to Rs. 1.03 crores, representing an impressive rise of about 106 percent YoY.

Shukra Pharmaceuticals Limited is engaged in the business of manufacturing, trading and exporting pharmaceutical products in both domestic and international markets.

Its product portfolio includes antibiotics, quinolones, macrolides, anti-bacterial, anti-fungal, anti-malarial, anti-viral, antiprotozoal, anti-anthelmintic, anti-depressant, anti-manic, beta-blockers, analgesic, muscle relaxants, anti-tuberculosis, vitamin products, anti-allergic, corticosteroids, hyper and hypoglycemic and others.

Written by Shivani Singh

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma stock hits upper circuit after securing order from Govt. of India to supply medical kits to Afghanistan appeared first on Trade Brains.